TY - JOUR
T1 - DNAMethylation Profiles of Ovarian Clear Cell Carcinoma
AU - Cunningham, Julie M.
AU - Winham, Stacey J.
AU - Wang, Chen
AU - Weiglt, Britta
AU - Fu, Zhuxuan
AU - Armasu, Sebastian M.
AU - McCauley, Bryan M.
AU - Brand, Alison H.
AU - Chiew, Yoke Eng
AU - Elishaev, Esther
AU - Gourley, Charlie
AU - Kennedy, Catherine J.
AU - Laslavic, Angela
AU - Lester, Jenny
AU - Piskorz, Anna
AU - Sekowska, Magdalena
AU - Brenton, James D.
AU - Churchman, Michael
AU - DeFazio, Anna
AU - Drapkin, Ronny
AU - Elias, Kevin M.
AU - Huntsman, David G.
AU - Karlan, Beth Y.
AU - Kobel, Martin
AU - Konner, Jason
AU - Lawrenson, Kate
AU - Papaemmanuil, Elli
AU - Bolton, Kelly L.
AU - Modugno, Francesmary
AU - Goode, Ellen L.
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research Inc.. All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. Methods: We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways. Results: Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 (N=137), Cluster 1 cases (N=134) presented at a more advanced stage, were less likely to be of Asian ancestry, and tended to have poorer outcomes including macroscopic residual disease following primary debulking surgery (P < 0.10). Subset analyses of targeted tumor sequencing and IHC data revealed that Cluster 1 tumors showed TP53 mutation and abnormal p53 expression, and Cluster 2 tumors showed aneuploidy and ARID1A/PIK3CA mutation (P < 0.05). Cluster-defining CpGs included 1,388 CpGs residing within 200 bp of the transcription start sites of 977 genes; 38% of these genes (N = 369 genes) were differentially expressed across cluster in transcriptomic subset analysis (P < 10-4). Differentially expressed genes were enriched for six immune-related pathways, including IFNα and IFNg responses (P < 10-6). Conclusions: DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways.
AB - Background: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. Methods: We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways. Results: Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 (N=137), Cluster 1 cases (N=134) presented at a more advanced stage, were less likely to be of Asian ancestry, and tended to have poorer outcomes including macroscopic residual disease following primary debulking surgery (P < 0.10). Subset analyses of targeted tumor sequencing and IHC data revealed that Cluster 1 tumors showed TP53 mutation and abnormal p53 expression, and Cluster 2 tumors showed aneuploidy and ARID1A/PIK3CA mutation (P < 0.05). Cluster-defining CpGs included 1,388 CpGs residing within 200 bp of the transcription start sites of 977 genes; 38% of these genes (N = 369 genes) were differentially expressed across cluster in transcriptomic subset analysis (P < 10-4). Differentially expressed genes were enriched for six immune-related pathways, including IFNα and IFNg responses (P < 10-6). Conclusions: DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways.
UR - http://www.scopus.com/inward/record.url?scp=85122884483&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0677
DO - 10.1158/1055-9965.EPI-21-0677
M3 - Article
C2 - 34697060
AN - SCOPUS:85122884483
SN - 1055-9965
VL - 31
SP - 132
EP - 141
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 1
ER -